William Marra & Asim M. Badaruzzaman
Smaller plaintiff firms are structurally outgunned by big defense. Will Marra and Asim Badaruzzaman of Certum Group on litigation finance, ops, and AI.
Tag: mass torts
When Drugs Become Warning Signs: Mass Torts, Ozempic & What’s Coming Next
Ozempic and similar GLP-1 drugs are fueling a wave of mass tort litigation. In this Trial Lawyer View episode, Michael Lynch shares what trial lawyers need to know about emerging claims, signature injuries, and strategies to hold pharmaceutical companies accountable.
How Smarter Case Development Can Free Your Firm to Win More Cases
Mass tort firms spend countless hours chasing medical records. Learn how Angeion Group’s blend of AI, nursing expertise, and client engagement helps trial lawyers validate cases, reduce bottlenecks, and scale growth.
Michael Lynch
Michael Lynch is a nationally recognized trial attorney leading a complex litigation firm advocating for victims of defective drugs, toxic exposure, NEC, personal injury, and more.
Troy Rafferty
Troy Rafferty, top trial lawyer and shareholder at Rafferty Domnick Cunningham & Yaffa, known for landmark mass tort verdicts and billion-dollar settlements.